منابع مشابه
Response to letter of Vahle et al.
several important points that deserve comment. The primary objective of our paper was to report the results of a standard two-year rat carcinogenicity study conducted with recombinant full-length human PTH (1-84) to comply with international regulatory guidelines. Dr. Vahle et al. are correct that our study did not directly compare the carcinogenic potential of PTH (1-84) and PTH (1-34), that i...
متن کاملKramer et al. respond to "Composite outcomes and paradoxes".
We thank Hernán et al. (1) for their thoughtful comments about the causal relationships among exposure, birth, and perinatal death; how selection bias can distort those relationships; and the role of composite outcomes. In our article (2), we do not claim composite outcomes to be a solution (“escape”) from the selection bias caused by conditioning on birth when analyzing the effect of pregnancy...
متن کاملResponse letter regarding the letter to the editors by Brown et al.
We read with interest the letter by Brown and colleagues, which focuses on our model’s assumptions regarding duration of cross-protection against non-vaccine HPV types (20, 30, 50 y and lifetime). Brown et al. begin by highlighting an article reviewing cross protection in different vaccine trials by Malag on et al., which suggests that AS04-adjuvanted HPV16/18 (bHPV, CervarixTM) vaccine-mediate...
متن کاملLetter to the Editor response: Nygaard et al.
The article by Nygaard and others (2016) proposes that applying batch correction approaches to microarray data from studies with unbalanced designs may inadvertently exaggerate the differences observed. In seeking to illustrate their point, Nygaard and others (2016) utilized a dataset (GSE61901) from a study we published (Towfic and others, 2014) and showed that one analysis pipeline utilizing ...
متن کاملResponse to comment by Moxon et al.
We would like to thank Clinical Science for the opportunity to respond to the letter [1] which suggests that while we have been able to show that PTP1B inhibitor, trodusquemine, decreases atherosclerotic plaque size as well as serum triglycerides and cholesterol, that we have not shown that it reverses the plaque size, using in vivo imaging techniques such as MRI scanning or ultrasound. Both Ld...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stroke
سال: 2007
ISSN: 0039-2499,1524-4628
DOI: 10.1161/01.str.0000251696.12445.c4